In human cancer, a positive (+) enrichment was observed in mutant KRAS patients compared to wild-type in LAC (n=3), PDAC, colorectal cancer (CRC), cholangiocarcinoma (CCA) and multiple myeloma (MM) (Supplementary Fig. 1d–j). This evidence concerns the gene KRAS and cholangiocarcinoma.